China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
MORRISTOWN, N.J., Feb. 18, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference, as follows.
| Date: | Wednesday, February 24, 2016 |
| Time: | 1:35 PM EST |
| Location: | New York, NY - The New York Palace Hotel |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
